Glycation endproducts in osteoporosis - Is there a pathophysiologic importance?

Clinica Chimica Acta

Volumn 371, Issue 1-2, 2006, Pages 32-36

  Hein, Gert E ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

AGE modification of proteins; Bone remodelling; Osteoblast; Osteoclast; Osteoporosis

Indexed keywords

CARBOHYDRATE; CELL ADHESION MOLECULE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

BONE REMODELING; BONE TURNOVER; CELL TYPE; CYTOKINE RELEASE; DIGESTION; FLUORESCENCE; GLYCATION; HUMAN; HYPOTHESIS; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; REVIEW;

BONE REMODELING; BONE RESORPTION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MYELOID CELLS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS;

EID: 33746760406     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.03.017     Document Type: Review

References (42)

1. NIH Consensus Development Panel on Osteoporosis. JAMA 285 (2001) 785-795
2. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., and Black D. Risk of mortality following clinical fractures. Osteoporos Int 11 7 (2000) 556-561
3. Mosekilde L., Ebbesen E.N., Tornvig L., and Thomsen J.S. Trabecular bone structure and strength - remodeling and repair. J Musculoskelet Neuronal Interact 1 1 (Sep 2000) 25-30
4. Bauer J. Bemerkungen zur Frage der Osteoporose. Wien Klin Wochenschr 39 (1963) 691-692
5. Parfitt A.M. Quantum concept of bone remodeling and turnover. Implications for the pathogenesis of osteoporosis. Calcif Tissue Int 28 (1997) 1-5
6. Nagaraj R.H., and Monnier V.M. Protein modification by the degradation products of ascorbate: formation of a novel pyrrole from the Maillard reaction of L-threose with proteins. Biochim Biophys Acta 15 (1995) 75-84
7. Niwa T., Katsuzuki T., Momoi T., et al. Modification of β2-m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney lnt 49 (1996) 861-867
8. Wells-Knecht K.J., Zyzyk D.V., Litchfield J.E., et al. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34 (1995) 3702-3709
9. Requena R.J., Fu M.X., Ahmed M.U., et al. Lipid peroxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol Dial Transplant 11 (1996) 48-53
10. Vlassara H., and Palace M.R. Diabetes and advanced glycation endproducts. J Intern Med 25 (2002) 87-101
11. Thornalley P.J. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol Noisy le grand vol. 44 (7) (1998) 1013-1023
12. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108 7 (2001) 949-955
13. Lu C., He J.C., Cai W., Liu H., Zhu L., and Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 101 32 (Aug 10 2004) 11767-11772
14. Dumitriu I.E., Baruah P., Valentinis B., et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174 12 (Jun 15 2005) 7506-7515
15. Wang X., Shen X., Li X., and Agrawal C.M. Age-related changes in the collagen network and toughness of bone. Bone 31 (2002) 107
16. Corthay A., Backlund J., Broddefalk J., et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol 28 (1998) 2580-2590
17. Corthay A., Backlund J., and Holmdahl R. Role of glycopeptide-specific T cells in collagen-induced arthritis: an example how post-translational modification of proteins may be involved in autoimmune disease. Ann Med 33 (2001) 456-465
18. Hofmann M.A., Schiekofer S., Isermann B., et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy demonstrated increased activation of the oxidative-stress sensitive transcription NF-kB. Diabetologia 42 (1999) 222-232
19. Bowie A., and O'Neill L.A. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59 (2000) 13-23
20. Yuan Z., Feldman R.J., Sun M., et al. Inhibition of JNK by cellular stress- and tumor necrosis factor a-induced AKT2 through activation of the NFkB pathway in human epithelial cells. J Biol Chem 277 (2002) 29973-29982
21. Gu L., Hagiwara S., Fan Q., et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 21 (2006) 299-313
22. Charoonpatrapong K., Shah R., Robling A.G., et al. HMGB1 expression and release by bone cells. J Cell Physiol 17 (2006) [Electronic publication ahead of print]
23. Hermani A., De Servi B., Medunjanin S., Tessier P.A., and Mayer D. S100A8 and S100A9 activate MAP kinase and NF-kappaB signalling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 312 (2006) 184-197
24. Kume S., Kato S., Yamagishi S., et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 20 (2005) 1647-1658
25. Singh R., Barden A., Mori T., and Beilin L. Advanced glycation end-products: a review. Diabetologia 44 (2001) 129-146
26. Raj D.S., Choudhury D., Welbourne T.C., and Levi M. Advanced glycation end-products: a nephrologist's perspective. Am J Kidney Dis 35 (2000) 365-380
27. Takahashi M., Suzuki M., Kushida K., Miyamoto S., and Inoue T. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Br J Rheumatol 36 (1997) 637-642
28. Hein G., Wiegand R., Lehmann G., Stein G., and Franke S. Advanced glycation end-products pentosidine and N-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42 (2003) 1242-1246
29. Odetti P., Rossi S., Monacelli F., et al. Advanced glycation end-products and bone loss during aging. Ann N Y Acad Sci 1043 (2005) 710-717
30. Miyata T., Notoya K., Yoshida K., et al. Advanced glycation end-products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8 (1997) 260-270
31. McCarthy A.D., Etcheverry S.B., Bruzzone L., Lettieri G., Barrio D.A., and Cortizo A.M. Nonenzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol 2 (2001) 16
32. McCarthy A.D., Etecheverry S.B., and Cortizo A.M. Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation. Acta Diabetol 36 (1999) 45-52
33. Cortizo A.M., Lettieri M.G., Barrio D.A., Mercer N., Etcheverry S.B., and McCarthy A.D. Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem 250 (2003) 1-10
34. Hein G., Weiβ Ch., Lehmann G., Niwa T., Stein G., and Franke S. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 65 (2006) 101-104
35. Katayama Y., Akatsy T., Yamamoto M., Kugai N., and Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 11 (1996) 931-937
36. Wang X., Li X., Shen C.-X., and Agrawal M. Age-related changes of noncalcified collagen in human cortical bone. Ann Biomed Eng 31 (2003) 1365-1371
37. Hernandez Ch.-J., Tang S.-Y., Baumbach B.-M., et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone 37 (2005) 825-832
38. Haynesworth S.E., Goshima J., Goldberg V.M., and Caplan A.I. Characterization of cells with osteogenic potential from human marrow. Bone 13 1 (1992) 81-88
39. Lazarus H.M., Hayneswoth S.E., Gerson S.L., Rosenthal N.S., and Caplan A.L. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 16 4 (1995) 557-564
40. Rellier N., Ruggiero-Lopez D., Lecomte M., Lagarde M., and Wiernsperger N. In vitro and in vivo acceleration of enzymatic glycosylation in diabetes. Life Sci 64 17 (1999) 1571-1583
41. MCKenna D.J., Nelson J., and Stitt A.W. Advanced glycation alters expression of the 67 kDa laminin receptor in retinal microvascular endothelial cells. Life Sci 4, 68 24 (2001) 2695-2703
42. Stitt A.W., Hughes S.J., Canning P., et al. Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. Diabetologia 47 10 (2004) 1735-1746